ADHD Across the Ages: Focus on the Child
neuroscienceCME Live and On Demand
Premiere Date: Wednesday, November 11, 2009Click here to access additional resources mentioned in the live broadcast.
This activity offers CE credit for:
- Physicians (CME)
- Pediatricians (AAP)
- Nurses (CNE)
- Pharmacists (ACPE)
- Psychologists (APA)
- Social Workers (NASW)
- Certified Case Managers (CCMC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, November 11, 2010
Note: Credit Is No Longer Available
 | Richard E. D'Alli, MD (Moderator) Associate Professor of Psychiatry and Pediatrics Duke University Medical Center Durham, NC |
 | Scott H. Kollins, PhD Chief Medical Officer, Holmusk Adjunct Professor of Psychiatry and Behavioral Science Duke University School of Medicine Durham, NC |
 | Alice R. Mao, MD Associate Professor of Psychiatry Menninger Department of Psychiatry and Behavioral Sciences Baylor College of Medicine Associate Medical Director Director of Psychopharmacology Research and Education Depelchin Children's Center Houston, TX |
Studies have shown that children with ADHD have higher rates of academic difficulties, social issues, and a number of comorbid psychiatric conditions compared to children without ADHD. These factors, and others, contribute to the high cost of care as well as diminished quality of life for children with ADHD. Applying the diagnostic criteria and unraveling the complexities of real-world patients can present a serious challenge to all clinicians. The symptom domains of ADHD—hyperactivity, impulsivity, and inattention—must often be diagnosed in the context of psychiatric comorbidities. The Multimodal Treatment Study of Children with ADHD (MTA) found that in a sample of 579 children, 31% had ADHD alone, 21% had oppositional symptoms, 12% had oppositional symptoms plus anxiety, 10% had anxiety symptoms, and 7% had comorbid conduct disorders.(1) Careful clinical assessment of the child focusing on family history and longitudinal course of the disease is pivotal in order to develop appropriate treatment planning. A multimodal treatment approach that includes both pharmacologic and behavioral interventions is prudent. Ongoing monitoring at regular intervals utilizing structured data tools should be implemented to evaluate efficacy, tolerability, and compliance. In this evidence-based neuroscienceCME Live and On Demand activity, the expert faculty will explore the complex presentations of ADHD and provide strategies for the assessment, diagnosis, and individualized multimodal management of children and adolescents with ADHD.
- Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 2001;40:147-158.
To improve knowledge and performance through utilization of evidence-based guidelines and current research on the diagnosis and long-term management of children and adolescents with ADHD.
At the end of this CE activity, participants should be able to:
- Integrate established practice parameters, screening tools, and clinical observation in the diagnosis of ADHD and the differentiation of ADHD with and without comorbid psychiatric symptoms and/or behavioral disorders.
- Routinely assess response to ADHD therapy using structured monitoring tools.
- Develop a comprehensive, individualized, and evidence-based treatment plan that combines pharmacological and behavioral strategies to improve outcomes for children and adolescents with ADHD.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Identify practice parameters, screening tools, and clinical observation in the diagnosis of ADHD and the differentiation of ADHD with and without comorbid psychiatric symptoms and/or behavioral disorders.
- Identify structured monitoring tools to routinely assess response to ADHD therapy.
- Compare and contrast options for a comprehensive, individualized, and evidence-based treatment plan that combines pharmacological and behavioral strategies to improve outcomes for children and adolescents with ADHD.
This educational activity is supported by an independent medical educational grant from Shire.
Physicians, pediatricians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, and other healthcare professionals interested in mental health.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited
by the Accreditation Council for Continuing
Medical Education to provide continuing
medical education for physicians.
CME Outfitters, LLC, designates this educational activity for
a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians
should only claim credit commensurate with the extent of
their participation in the activity.
AAP Credit (Pediatricians):
This continuing medical education
activity has been reviewed by the American Academy of
Pediatrics and is acceptable for a maximum of 1.0 AAP credits.
These credits can be applied toward the AAP CME/CPD Award
available to Fellows and Candidate Members of the American
Academy of Pediatrics.
CNE Credit (Nurses):
This continuing nursing education activity was approved by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
It has been assigned approval code 7ZDSHF-10. 1.0 contact hours will be awarded upon successful completion.
CEP Credit (Psychologists):
CME Outfitters is approved
by the American Psychological Association to sponsor
continuing education for psychologists. CME Outfitters
maintains responsibility for this program and its content.
(1.0 CE credits)
NASW Credit (Social Workers):
This program was approved
by the National Association of Social Workers (provider
#886407722) for 1 continuing education contact hour.
CCMC Credit (Certified Case Managers):
This program
has been approved for 1 hour by the Commission for Case
Manager Certification (CCMC).
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited
by the Accreditation Council for Pharmacy Education
as a provider of continuing pharmacy education.
1.0 contact hours (0.1 CEUs)
Universal Activity Number:
376-000-09-028-L01-P (live presentation)
376-000-09-028-H01-P (recorded programs)
Activity Type: knowledge-based
Post-tests, credit request forms, and activity evaluations can be
completed online at www.neuroscienceCME.com (click on the
Testing/Certification link under the Activities tab–requires free
account activation), and participants can print their certificate
or statement of credit immediately (70% pass rate required).
Otherwise, participants should fully complete and return both
the credit request form and activity evaluation located within the
course guide for this activity. A certificate or statement of credit
will be mailed within 4–6 weeks to all who successfully complete
these requirements. This website supports all browsers except
Internet Explorer for Mac. For complete technical requirements
and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. D'Alli has no disclosures to report.
Dr. Kollins has disclosed that he receives grant support from Addrenex Pharmaceuticals, Inc., Comentis, Environmental Protection Agency, National Institute on Drug Abuse, National Institute of Environmental Health Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, and Shire Pharmaceuticals. He serves as a consultant to Addrenex Pharmaceuticals, Inc., Comentis, National Institute on Drug Abuse, National Institutes of Health, Otsuka America Pharmaceutical, Inc., and Shire Pharmaceuticals.
Dr. Mao has disclosed that she is on the speakers bureau of Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., Novartis Pharmaceuticals Corporation, Noven Pharmaceuticals, Inc., Ortho-McNeil Janssen Scientific Affairs, LLC, Pfizer Inc., and Shire Pharmaceuticals.
Howard Bliwise, MD (Content/Peer Reviewer) has no disclosures to report.
Nancy Jennings, MSN, MBA, MHA, RNC (Content/Peer Reviewer) has no disclosures to report.
Ruth Cody, BSN, RN-BC (Content/Peer Reviewer) has no disclosures to report.
Philip Harvey, PhD (Content/Peer Reviewer) has no disclosures to report.
Greg Kirk, MSW, LCSW (Content/Peer Reviewer) has no disclosures to report.
Monique Johnson, MD, CCMEP (Planning Committee) has no disclosures to report.
Sharon Tordoff, CCMEP (Planning Committee) has no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Shire Pharmaceuticals do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
TV-062-111109-19
